Quince Therapeutics, Inc. (QNCX)
Healthcare
Biotechnology
25.30 $
+8.3%
vs. previous close
Closing price · As of: 3. Aug 2026
Quince Therapeutics, Inc. (QNCX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -7.6 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.8 | -4.8 | -6.1 | -8.4 | -8.7 | -7.3 | -7.6 | -9.6 | -11 | -9.9 | -10 | -7.6 | -39 | |
| 0.0 | 0.0 | 0.3 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| 1.3 | 1.3 | 1.1 | 1.3 | 1.2 | 1.1 | 1.1 | 1.4 | 1.3 | 1.3 | 1.2 | 1.3 | 5.0 | |
| 1.3 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.2 | -0.1 | 0.3 | -0.8 | -1.4 | -0.2 | 1.9 | 2.1 | -1.9 | 0.2 | 12 | -14 | -3.7 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.2 | |
| -20 | 3.6 | – | 8.9 | -5.0 | 7.1 | 11 | 11 | 6.0 | -1.8 | – | 12 | – | |
| 0.0 | – | – | 64 | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | 0.0 | 0.0 | 0.0 | – | – | – | -5.5 | – | |
| 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | -5.0 | 0.0 | 0.1 | 14 | 1.4 | 2.0 | 9.4 | 27 | |
| -24 | -1.0 | -0.9 | 1.1 | -14 | -5.2 | 3.5 | 1.6 | 9.1 | -10 | -0.6 | 12 | 10 | |
| -3.8 | -4.8 | -6.1 | -8.4 | -8.8 | -7.3 | -7.7 | -9.7 | -12 | -10 | -10 | -7.6 | -40 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.